Based in San Francisco, Dr. Birchenough will lead BMO coverage of the U.S. biotechnology sector.
Also joining the firm is Dr. Birchenough’s longstanding team of Nicholas Abbott and Charles Whitesell.
'Research coverage of the biotechnology sector is a priority for us as we expand our equity research Healthcare team', said Jack Blackstock, Co-Head of Equity Research, BMO Capital Markets. 'The addition of Jim and his team will significantly strengthen our healthcare coverage and enhance the knowledge and investment ideas we bring forth to our clients'.
With more than two decades of experience as a physician, pharmaceutical industry veteran and sell side analyst, Dr. Birchenough has covered a broad range of small, mid- and large-cap biotech companies. He has an emphasis on clinical discovery and emerging technologies and companies and is highly rated in various investor surveys. He holds a Post Graduate Medical Residency and a Medical Doctorate from McMaster University and a Bachelor of Science in Physiology from McGill University.